Non-myeloablative transplantation incorporating peri-transplant-rituximab can lead to a two-year event-free survival (EFS) of 72%, according to results of a prospective trial of 51 patients with CD20+ B-cell non-Hodgkin lymphoma (B-NHL). Patients were a median age of 54 years (range, 33-67) and received rituximab 375 mg/m2 on day -8 and in four weekly doses beginning day +21. Cumulative incidence of grade II-IV acute GVHD at six months was 25%, and grade III-IV GVHD was 11%. Two-year EFS was significantly higher in chemosensitive patients compared to chemorefractory patients pre-transplant: 84% vs. 30%, respectively (p<0.001). The authors concluded that early referral for non-myeloablative transplantation should be considered in poor-risk B-NHL patients while chemosensitivity is preserved.
Sauter CS, et al. Biol Blood Marrow TransplantChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Peri-Transplant Rituximab in Lymphoma Can Lead to Durable Event-Free Survival
Dec 2013